On August 12, 2022, the U.S. Food and Drug Administration (FDA) approved Guardant360® CDx liquid biopsy test as a companion diagnostic (CDx) to select patients with unresectable or metastatic HER2-mutant non-small cell lung cancer (NSCLC), whose tumors have activating human epidermal growth factor receptor 2 HER2 (ERBB2) mutations, for treatment with AstraZeneca and Daiichi Sankyo's Enhertu® (fam-trastuzumab deruxtecan-nxki).
For more information, read Guardant Health's announcement.
Posted 8/15/2022
